PMV Pharmaceuticals
Signal active
Investment Firm
Overview
PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.
Highlights
Founded
2013
Industry
Biotechnology
Employees
51-100
Investment
2
Lead Investment
0
Exits
1
Stages
Early Stage Venture
Investor Type
N/A
Location
United States, North America
Contact Information
Social
Profile Resume
PMV Pharmaceuticals, established in 2013 and headquartered in United States, North America., specializes in Early Stage Venture investments across Biotechnology, Health Care, Medical, Life Science, CleanTech, Financial Services, Venture Capital, Finance. The organization boasts a portfolio of 2 investments, with an average round size of $9.4M and 1 successful exits. Their recent investments include Apitope, Limburgse Reconversie Maatschappij, Vesalius Biocapital Partners, Arthurian Life Sciences. The highest investment round they participated in was $926.9M. Among their most notable exits are Apitope and Limburgse Reconversie Maatschappij. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
PMV Pharmaceuticals has made 2 investments. Their most recent investment was on Sep 29, 2015, when Apitope raised $13.5M.
investments
2
Diversity investments
0
Lead investments
0
Number of exits
1
Investments
2
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Jan 23, 2013 | - | - | 5.3M |
| Sep 29, 2015 | Apitope | Biotechnology | 13.5M |
ApitopeExits
1
Funding Timeline
Funding rounds
2
Investors
11
Funds
0
Funding Rounds
2
PMV Pharmaceuticals has raised 2 rounds. Their latest funding was raised on Sep 29, 2015 from a Series B - Apitope round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Jan 23, 2013 | Series A - FF Pharma | - | 5.3M | - |
| Sep 29, 2015 | Series B - Apitope | - | 13.5M | - |
Investors
23
PMV Pharmaceuticals is funded by 23 investor(s). Wellington Management and OrbiMed Kantor are the most recent investors.
| Investor Name | Lead Investor | Funding Round | Money Raised |
|---|---|---|---|
RA Capital Management | No | Series D - PMV Pharmaceuticals | 70.0M |
Avoro Capital Advisors | No | Series D - PMV Pharmaceuticals | 70.0M |
OrbiMed | No | Series D - PMV Pharmaceuticals | 70.0M |
Wellington Management | No | Series D - PMV Pharmaceuticals | 70.0M |
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.